Company: CRNX
Filing Date: 2025-06-26
Form Type: 8-K
Source: 0000950170-25-090405
Chunk: 0

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-06-26
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On June 26, 2025, at 9:00 am Eastern Time, Crinetics Pharmaceuticals, Inc. (the “ Company”) hosted an in-person and virtual Research and Development Day (“ R& D Day”) in New York. The R& D Day included a presentation that provided an update, including preclinical data on the Company’s early-stage pipeline assets, next steps and portfolio strategy to drive long-term value. Key topics included:

• CRN12755, a Thyroid Stimulating Hormone Receptor (“ TSHR”) antagonist, for Graves’ disease, including Graves’ hyperthyroidism and Graves’ orbitopathy (Thyroid Eye Disease, or “ TED”)

• CRN10329, an SST3 agonist, for autosomal dominant polycystic kidney disease (“ ADPKD”)

• Nonpeptide drug conjugate (NDC) platform, including CRN09682 for NETs and other SST2+ tumors

During the presentation, the Company referenced the slide presentation attached as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference. The slide presentation and a live audio webcast of the presentation have been made available under the “ Investors” section of the Company’s website.

The information contained in this Item 7.01, including in Exhibit 99.1 hereto, is being “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “ Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.